| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a5511d171c3e1eb82c61cf7e5ad1663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f41a868f49ca4f32d18d861e3afb411 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2019-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35d9581b606d784942a5497548ed126b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc1c00fbf9bdeb4794a7e7140890868b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d91a691a3c24d18f4bdc7c7bbfba33b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b98ffc0a6a38f8481f97ea5e5e72ef2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a09b382a981ab4d0b206e77ef83b6da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_808c610b633444dcb31094ee719e00df |
| publicationDate |
2021-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3850010-A1 |
| titleOfInvention |
Improved anti-flt3 antigen binding proteins |
| abstract |
The present invention provides novel human fms related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and/or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3xCD3 antibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention. |
| priorityDate |
2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |